Welcome to our dedicated page for PANBELA THERAPEUTICS news (Ticker: PBLA), a resource for investors and traders seeking the latest updates and insights on PANBELA THERAPEUTICS stock.
Panbela Therapeutics, Inc. (NASDAQ: PBLA) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address unmet medical needs in cancer treatment and prevention. Headquartered in Minneapolis, Panbela's primary assets include Ivospemin (SBP-101) and Flynpovi.
Panbela's core business revolves around advancing its drug pipeline through clinical trials. The company has made significant strides in 2023 and early 2024, particularly with its Phase III ASPIRE trial, which targets untreated metastatic pancreatic ductal adenocarcinoma. This trial has surpassed 50% enrollment, bringing it closer to its goal of enrolling approximately 600 patients by Q1 2025. The recent approval of Onivyde in the same therapeutic area for the first time in over a decade augments Panbela's optimism regarding its interim analysis and potential for providing additional treatment options.
Financially, Panbela reported a net loss of $6.5 million in 2023's fourth quarter, with general and administrative expenses decreasing to $0.9 million. Research and development expenses rose to $6.1 million, reflecting the company's robust commitment to its clinical programs. As of December 31, 2023, Panbela had $2.6 million in cash and current assets totaling $3.1 million against current liabilities of $12.3 million. The completion of a public offering in January 2024 raised approximately $9 million in gross proceeds, bolstering the company's financial standing.
Panbela collaborates with renowned institutions like Johns Hopkins University School of Medicine, enhancing its research capabilities. The company's development programs encompass various cancers, including familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention, ovarian cancer, and diabetes.
- Ivospemin (SBP-101): This proprietary polyamine analogue aims to inhibit polyamine metabolism in pancreatic ductal adenocarcinoma and other tumors. Clinical studies have shown promising results, including a median overall survival of 14.6 months and an objective response rate of 48%, outperforming standard chemotherapy regimens. Ivospemin has not exacerbated chemotherapy-related adverse events, supporting its continued evaluation in the ASPIRE trial.
- Flynpovi™: A combination of CPP-1X (eflornithine) and sulindac, Flynpovi inhibits polyamine synthesis and enhances polyamine catabolism. Phase III trials have demonstrated its efficacy in preventing precancerous sporadic adenomas and delaying surgical events in FAP patients. The safety profile of Flynpovi supports its ongoing evaluation.
- CPP-1X (Eflornithine): Developed as a single agent for indications like gastric cancer prevention and recent onset Type 1 diabetes, CPP-1X has shown potential activity and tolerability in preclinical and early-phase trials.
Panbela's common stock is listed on the OTCQB market under the symbol “PBLA”. The company remains dedicated to advancing its clinical programs and maximizing stockholder value through strategic initiatives and potential regulatory approvals.
Panbela Therapeutics (Nasdaq: PBLA) announced a conference call on August 15, 2022, to discuss its second-quarter results for the period ended June 30, 2022. The company is focused on developing therapeutics for serious unmet medical needs, with ongoing clinical trials for SBP-101 and Flynpovi. SBP-101 has shown a median overall survival of 14.6 months in pancreatic cancer patients, while Flynpovi demonstrated over 90% effectiveness in preventing pre-cancerous adenomas in a Phase 3 trial. The call will start at 4:30 PM ET.
Panbela Therapeutics announced promising preclinical data for its drug SBP-101, showing a 42% increase in median survival in a mouse model of ovarian cancer. In vitro studies demonstrated significant reduction in viability across multiple cancer cell types. The company plans to launch a clinical program for SBP-101 in ovarian cancer in 2022, complementing its existing global trial for pancreatic cancer. SBP-101's promising results include a median overall survival of 14.6 months in pancreatic cancer patients, with an objective response rate of 48%.
Panbela Therapeutics announced the successful acquisition of Cancer Prevention Pharmaceuticals for a mix of stock and milestone payments. This merger targets a $5 billion market opportunity, focusing on cancer types including familial adenomatous polyposis and pancreatic cancer. The acquisition aims to enhance their clinical pipeline by integrating four clinical-stage assets, among which two are late-stage. This strategic move is expected to bolster shareholder value and improve treatment options for patients.
Panbela Therapeutics (Nasdaq: PBLA) provided a business update and financial results for Q1 2022, highlighted by a net loss of $3.7 million, or $0.27 per diluted share. Key developments included the agreement to acquire Cancer Prevention Pharmaceuticals (CPP) targeting a $5 billion market, the initiation of the ASPIRE trial for SBP-101 in pancreatic cancer, and a successful R&D Day presentation. General and administrative expenses rose to $1.8 million, while research and development costs increased to $2.2 million due to the ASPIRE trial launch.
Panbela Therapeutics (Nasdaq: PBLA) will host an R&D call on May 03, 2022, at 9:00 AM ET, featuring experts discussing the investigational drug SBP-101 for ovarian cancer treatment. The drug is a polyamine metabolism modulator showing promise in clinical studies, achieving a median overall survival of 12.0 months and an objective response rate of 48% in pancreatic cancer patients. The call is accessible via toll-free numbers and a provided event link. Replay details will also be available post-event.
Panbela Therapeutics, Inc. (Nasdaq: PBLA) will host a conference call on May 12, 2022, at 4:30 PM ET to discuss its first-quarter results for the period ending March 31, 2022. The company is advancing SBP-101, a therapeutic designed for pancreatic cancer treatment, showing a median overall survival of 12 months and an objective response rate of 48% in clinical trials. Interested parties can join via phone or webcast. For further details, visit www.panbela.com.
Panbela Therapeutics (Nasdaq: PBLA) has presented promising results for SBP-101, a polyamine metabolism modulator, in treating ovarian cancer at the AACR Annual Meeting 2022. The study, conducted in collaboration with Johns Hopkins University, showed that SBP-101 significantly prolonged survival and reduced tumor burden in a murine model. The treatment demonstrated significant efficacy at doses of 24 mg/kg and 6 mg/kg. The data reveals SBP-101's potential in clinical management, with expectations to advance ovarian cancer studies later this year.
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announced significant corporate and financial progress in its latest update on March 24, 2022. Key highlights include an agreement to acquire Cancer Prevention Pharmaceuticals, Inc., enhancing its pipeline targeting a $5 billion market. The company initiated the ASPIRE Phase II/III trial for its drug SBP-101 and plans to expand its development into ovarian cancer. Financially, the company reported a Q4 net loss of $3.5 million, with total cash of $11.9 million. Management expresses optimism for future growth through ongoing trials and acquisitions.
Panbela Therapeutics (Nasdaq: PBLA) announced participation in a panel discussion titled, "Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology," at the Maxim Virtual Growth Conference on March 28, 2022. The event starts at 12:00 pm ET and will stream virtually from March 28-30, 2022, featuring an on-demand presentation by the company. Their product candidate, SBP-101, has shown promising results in clinical studies with a median overall survival of 12.53 months and an objective response rate of 48%, indicating potential advantages over standard chemotherapy.
Panbela Therapeutics (Nasdaq: PBLA) announced participation in the 34th Annual Roth Conference on March 14, 2022, at 11:30 AM PT, with a webcast available online. The company is focused on developing SBP-101, a proprietary therapy for metastatic pancreatic ductal adenocarcinoma, showing promising clinical results including a median overall survival of 12 months and an objective response rate of 48%. Panbela aims to address urgent medical needs in cancer treatment, with significant potential for future development.
FAQ
What is the current stock price of PANBELA THERAPEUTICS (PBLA)?
What is the market cap of PANBELA THERAPEUTICS (PBLA)?
What is Panbela Therapeutics' primary focus?
What are Panbela's lead assets?
What is the status of the Phase III ASPIRE trial?
What recent financial achievements has Panbela reported?
What collaborations does Panbela engage in?
What are the potential benefits of Ivospemin (SBP-101)?
What results have been observed with Flynpovi?
What is CPP-1X (Eflornithine) being developed for?
Where is Panbela's stock listed?
What is the significance of Panbela's recent public offering?
